Quote:
Originally Posted by Conductor71
What is annoying is that it's taken over 20 years for a pharamaceutical company to actually develop this therapy. I suspect it's because pharma didn't think this would compete with oral Sinemet, despite the evidence that a continuous infusion greatly reduces dyskinesia and on/off effects- really it's better for us over all. Now that Solvay sees a market in this treatment, I'm guessing it's the FDA bureaucracy holding things up? Anyone know the story behind this treatment?
Laura
|
Never mind. Clinical trials once again use the fail proof placebo control; we'll be lucky if duodopa bounces over to MJFF for further research and tinkering before it ends up back on the FDA "fast track"- anyone got another 21 years to spare?
-L